ארביטוקס 5 מ"ג/מ"ל - Erbitux 5 mg/ml
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors | ||||||||||||||||||||||||||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||||||||||||||||||||||||||
| צ×רת ××ª× | ת××-×ר××× - I.V | ||||||||||||||||||||||||||||||
| צ×רת ××× ×× | ת×××¡× ×××× ×¤××××, SOLUTION FOR INFUSION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||||||||||||||||||||||||||
| ×ת×××× | Erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (EGFR) - expressing, RAS wild-type metastatic colorectal cancer⢠In combination with irinotecan-based chemotherapy⢠In first-line in combination with FOLFOX⢠as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanErbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (SCCHN)⢠in combination with radiation therapy for locally advanced disease⢠in combination with platinum-based chemotherapy for recurrent and/or metastatic disease⢠as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease
| ||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| ×ת××ת ××× ×× | Posology and method of administration | ||||||||||||||||||||||||||||||
| ×ת××××ת × ×× | Contraindications | ||||||||||||||||||||||||||||||
| ת×פע×ת ××××× | Undesirable effects | ||||||||||||||||||||||||||||||
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction | ||||||||||||||||||||||||||||||
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation | ||||||||||||||||||||||||||||||
| פר×ק×××× ×××§× | Pharmacodynamic Properties | ||||||||||||||||||||||||||||||
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties | ||||||||||||||||||||||||||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  | ||||||||||||||||||||||||||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ×ר××××קס 5 ×"×/×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | MERCK HEALTHCARE KGAA, GERMANY |
| ×©× ××¢× ×ר×ש×× | MERCK SERONO LTD |
| ר×ש××× | ת×ר×× ××ש×: 04/2008. ר×ש××× ×ת×ר××: 07/2014 |
| ת×ר×× ×¢×××× ××ר×× | 05/03/2025 |
ת××× ×ª ×ר×××
×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
השינוי האחרון נעשה בֹ־5 במרץ 2025 ב־13:19